Theradiag SA
PAR:ALTER
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Theradiag SA
Gross Profit
Theradiag SA
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Theradiag SA
PAR:ALTER
|
Gross Profit
€10.1m
|
CAGR 3-Years
11%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Edap Tms SA
NASDAQ:EDAP
|
Gross Profit
€30m
|
CAGR 3-Years
7%
|
CAGR 5-Years
10%
|
CAGR 10-Years
8%
|
|
|
Biomerieux SA
PAR:BIM
|
Gross Profit
€2.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
9%
|
|
|
S
|
SMAIO SA
PAR:ALSMA
|
Gross Profit
€4.2m
|
CAGR 3-Years
32%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
Amplitude Surgical SA
PAR:AMPLI
|
Gross Profit
€86.5m
|
CAGR 3-Years
30%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Mauna Kea Technologies SA
PAR:ALMKT
|
Gross Profit
€3.2m
|
CAGR 3-Years
46%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-2%
|
|
Theradiag SA
Glance View
Theradiag SA engages in the distribution, development and manufacturing of in vitro diagnostic and theranostics tests. The company is headquartered in Croissy-Beaubourg, Ile-De-France. The company went IPO on 2012-12-11. The firm develops and offers product panels for diagnosing autoimmune diseases, allergies, and infectious diseases. TheraDiags product offering consists of tests using a range of techniques (Elisa, rapid tests, immunofluorescence, Dot, immunochemical tests, molecular biology, etc.) as well as a range of automatic devices and solutions for high-speed diagnostics based on Luminexs Multiplex technology. The company has also developed a range of theranostic diagnostics commercialized under the Lisa-Tracker brand which provide monitoring of patients treated by anti-TNF monoclonal antibodies. TheraDiag is active in more than 30 countries, as an independent distributor.
See Also
What is Theradiag SA's Gross Profit?
Gross Profit
10.1m
EUR
Based on the financial report for Jun 30, 2023, Theradiag SA's Gross Profit amounts to 10.1m EUR.
What is Theradiag SA's Gross Profit growth rate?
Gross Profit CAGR 5Y
8%
Over the last year, the Gross Profit growth was 17%. The average annual Gross Profit growth rates for Theradiag SA have been 11% over the past three years , 8% over the past five years .
